An Ambispective, Non-interventional, Multiple Cohort Study to Assess the Management of Osimertinib Treatment in Patients With EGFRm Non-small Cell Lung Cancer Under Real-world Conditions in Spain
Latest Information Update: 22 Jan 2025
At a glance
- Drugs Osimertinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms OSIREAL
- Sponsors AstraZeneca
Most Recent Events
- 16 Oct 2024 Drug regimen changed with addition of new cohort assessing Osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first- line treatment (FLAURA2 regimen)
- 18 Mar 2024 Planned number of patients changed from 300 to 400.
- 09 Oct 2023 New trial record